Predict your next investment

Venture Capital
forbion.com

See what CB Insights has to offer

Investments

126

Portfolio Exits

34

Funds

12

Partners & Customers

2

About Forbion Capital Partners

Forbion Capital Partners invests in Life Sciences and Biomedical Technology companies developing drugs and technologies, with a clear focus on product development. The Forbion team is specialized in the evaluation of late stage preclinical / early stage clinical development programs. Forbion also invests in medical device companies with a focus on interventional cardiology and gastroenterology. The Forbion team began operating in 2000 as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December 2006 the group broadened its investor base, became independent, and changed its name to Forbion Capital Partners. Forbion currently has EUR 200 million under management.

Forbion Capital Partners Headquarter Location

Gooimeer 2-35

Naarden, 1411 DC,

Netherlands

+31 (0) 35 699 30 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Forbion Capital Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Forbion Capital Partners in 1 Expert Collection, including CB Insights Healthcare Smart Money Investors - 2020.

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Research containing Forbion Capital Partners

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Forbion Capital Partners in 3 CB Insights research briefs, most recently on Feb 16, 2021.

Latest Forbion Capital Partners News

Precirix raises EUR 80m in Series B, Gimv further supports the development of precision radiopharmaceuticals

Mar 16, 2022

16/03/2022 - 08:00 | Portfolio Brussels, Belgium, 16 March 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investor INKEF Capital, alongside Jeito Capital and Forbion Capital Partners. The company’s existing shareholders Gimv, HealthCap, Novo Holdings, Pontifax Venture Capital, V-Bio Ventures, BioMed Partners, as well as the seed investors, continue to support the company and participated in the round. The proceeds of this financing round will fund the development and expansion of Precirix’ pipeline. More specifically, the company will advance CAM-H2 through its ongoing Phase I/II study and plans to bring additional novel radiopharmaceuticals to the clinic. Michaël Vlemmix, Principal in Gimv’s Health & Care platform and board member indicates: “Precirix has made significant progress since its Series A in 2018. The additional financing will allow us to further leverage the radiopharmaceutical platform, diversify the pipeline and continue to advance the clinical developments with a core goal to bring new medicines to patients. Backed by some of the strongest names in our industry, the company holds a solid foundation to further build on its story towards success”. For more information, please read the full press release from Precirix attached.

Forbion Capital Partners Investments

126 Investments

Forbion Capital Partners has made 126 investments. Their latest investment was in Precirix as part of their Series B on March 3, 2022.

CBI Logo

Forbion Capital Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/16/2022

Series B

Precirix

$87.92M

Yes

7

2/23/2022

Seed VC

Complement Therapeutics

$5.66M

Yes

4

12/20/2021

Series B

Armgo Pharma

$35M

Yes

6

12/17/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

12/16/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/16/2022

2/23/2022

12/20/2021

12/17/2021

12/16/2021

Round

Series B

Seed VC

Series B

Series C

Series B

Company

Precirix

Complement Therapeutics

Armgo Pharma

Subscribe to see more

Subscribe to see more

Amount

$87.92M

$5.66M

$35M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

4

6

10

10

Forbion Capital Partners Portfolio Exits

34 Portfolio Exits

Forbion Capital Partners has 34 portfolio exits. Their latest portfolio exit was Gyroscope Therapeutics on December 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/22/2021

Acquired

$99M

19

11/22/2021

Acquired

$99M

6

9/21/2021

Acquired

$99M

2

3/31/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/7/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/22/2021

11/22/2021

9/21/2021

3/31/2021

10/7/2020

Exit

Acquired

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

19

6

2

10

10

Forbion Capital Partners Fund History

12 Fund Histories

Forbion Capital Partners has 12 funds, including Forbion Growth Opportunities Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/9/2022

Forbion Growth Opportunities Fund II

$500M

1

4/20/2021

Forbion Growth Opportunities Fund I

$428M

1

12/8/2020

Forbion V

$557.1M

4

7/9/2020

Forbion Growth Fund

$99M

10

10/1/2018

Forbion IV

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

6/9/2022

4/20/2021

12/8/2020

7/9/2020

10/1/2018

Fund

Forbion Growth Opportunities Fund II

Forbion Growth Opportunities Fund I

Forbion V

Forbion Growth Fund

Forbion IV

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$500M

$428M

$557.1M

$99M

$99M

Sources

1

1

4

10

10

Forbion Capital Partners Partners & Customers

2 Partners and customers

Forbion Capital Partners has 2 strategic partners and customers. Forbion Capital Partners recently partnered with Lonza Group, and BioGeneration Ventures on December 12, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

12/14/2020

Vendor, and Client

Switzerland, and Netherlands

Lonza, Forbion and BioGeneration Ventures Announce Collaboration for Development and Manufacture of Biologics for Portfolio Companies

Forbion operates a joint venture with BioGeneration Ventures , the manager of seed and early-stage funds , especially focused on Benelux and Germany .

1

12/10/2020

Partner

Netherlands

Subscribe to see more

Subscribe to see more

10

Date

12/14/2020

12/10/2020

Type

Vendor, and Client

Partner

Business Partner

Country

Switzerland, and Netherlands

Netherlands

News Snippet

Lonza, Forbion and BioGeneration Ventures Announce Collaboration for Development and Manufacture of Biologics for Portfolio Companies

Forbion operates a joint venture with BioGeneration Ventures , the manager of seed and early-stage funds , especially focused on Benelux and Germany .

Subscribe to see more

Subscribe to see more

Sources

1

10

Forbion Capital Partners Team

13 Team Members

Forbion Capital Partners has 13 team members, including current Chief Financial Officer, Vincent Van Houten.

Name

Work History

Title

Status

Vincent Van Houten

Chief Financial Officer

Current

Vincent Van Houten

Controller

Current

Geert Jan Mulder

Managing Partner

Current

Martien Van Osch

Managing Partner

Current

Sander Slootweg

Managing Partner, Owner

Current

Name

Vincent Van Houten

Vincent Van Houten

Geert Jan Mulder

Martien Van Osch

Sander Slootweg

Work History

Title

Chief Financial Officer

Controller

Managing Partner

Managing Partner

Managing Partner, Owner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.